* AMPA-sensitive glutamate receptors are crucial to the structural and dynamic properties of the brain, to the development and function of the central nervous system, and to the treatment of neurological conditions from depression to cognitive impairment. However, the molecular principles underlying AMPA receptor activation have remained elusive. We determined multiple x-ray crystal structures of the GluA2 AMPA receptor in complex with a Conus striatus cone snail toxin, a positive allosteric modulator, and orthosteric agonists, at 3.8 to 4.1 angstrom resolution. We show how the toxin acts like a straightjacket on the ligand-binding domain (LBD) "gating ring," restraining the domains via both intra-and interdimer cross-links such that agonist-induced closure of the LBD "clamshells" is transduced into an irislike expansion of the gating ring. By structural analysis of activation-enhancing mutants, we show how the expansion of the LBD gating ring results in pulling forces on the M3 helices that, in turn, are coupled to ion channel gating.
* AMPA-sensitive glutamate receptors are crucial to the structural and dynamic properties of the brain, to the development and function of the central nervous system, and to the treatment of neurological conditions from depression to cognitive impairment. However, the molecular principles underlying AMPA receptor activation have remained elusive. We determined multiple x-ray crystal structures of the GluA2 AMPA receptor in complex with a Conus striatus cone snail toxin, a positive allosteric modulator, and orthosteric agonists, at 3.8 to 4.1 angstrom resolution. We show how the toxin acts like a straightjacket on the ligand-binding domain (LBD) "gating ring," restraining the domains via both intra-and interdimer cross-links such that agonist-induced closure of the LBD "clamshells" is transduced into an irislike expansion of the gating ring. By structural analysis of activation-enhancing mutants, we show how the expansion of the LBD gating ring results in pulling forces on the M3 helices that, in turn, are coupled to ion channel gating. F ast excitatory signal transduction at the chemical synapses of the brain is largely mediated by the activation of ionotropic glutamate receptors (iGluRs) by glutamate released from presynaptic neurons (1) . Within the iGluR family of receptors are a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA), kainate (KA), and N-methyl-D-aspartate (NMDA) subtypes, receptors that are all activated by glutamate and related in amino acid sequence, subunit stoichiometry, and domain structure, yet distinct in overall architecture, pharmacology, and biophysical characteristics. AMPA receptors undergo fast, submillisecond activation by glutamate, leading to depolarization of the postsynaptic membrane and relief of magnesium block of NMDA receptors, followed by rapid desensitization and deactivation on a millisecond time scale (1) . AMPA receptor activity is fundamental to synaptic transmission, synaptic plasticity, and homeostatic scaling (2) , and allosteric potentiators that slow desensitization and/or deactivation enhance synaptic currents and task-dependent neuron firing and show promise in the treatment of mild cognitive impairment and depression (3) . By contrast, allosteric antagonists that diminish glutamate-induced AMPA receptor activity reduce glutamate-induced synaptic currents and are promising agents for the treatment of seizure disorders (4) . Thus, understanding the molecular principles of AMPA receptor activation and action by allosteric modulators is important for continued development of new therapeutic strategies.
AMPA receptors are tetrameric complexes composed of subunits with a modular domain arrangement, beginning with the amino-terminal domain (ATD), the ligand-or agonist-binding domain (LBD), and the pore-forming transmembrane domain (TMD) (5) . Whereas the ATDs and LBDs are organized as dimers of dimers, the TMD harbors approximate fourfold symmetry, thus yielding a symmetry mismatch between the LBD and TMD layers and giving rise to two nonequivalent subunit pairs, A/C and B/D (6) . Hence, the mechanism and efficacy of transduction of agonist binding to ion channel gating may differ between the A/C and B/D subunit pairs. Because AMPA receptors undergo rapid and nearly complete desensitization in the continued presence of agonist (7), it has proven difficult to elucidate high-resolution structures of agonist-bound, activated states and to define mechanisms by which the chemical potential of agonist binding is transduced into the mechanical force of ion channel gating.
Here, we report x-ray crystal structures of an intact, rat GluA2 AMPA receptor in complex with a homodimeric Conus striatus cone snail toxin, con-ikot-ikot (8); (R,R)-2b, a high-affinity, twofold symmetric, positive allosteric modulator (9); the partial agonist KA (10); or the potent partial agonist fluorowillardiine (FW) (11) . To do this, we expressed, purified, and solved the structure of con-ikot-ikot, a disulfide bond-rich polypeptide previously shown to induce paralysis in fish and potently and selectively block desensitization of AMPA receptors (8) (fig. S1 ). We next screened single-amino acid mutants of the GluA2 receptor for enhanced thermostability in detergent micelles by fluorescence-detection size-exclusion chromatography (FSEC) (12) because the native, agonist-bound receptor is unstable in detergent micelles. Substitution of 10 amino acids in the TMD (construct GluA2 cryst1 ) gives rise to a receptor with enhanced stability and with retention of agonist-induced ion channel gating activity ( fig.  S2 ). By combining con-ikot-ikot toxin with the GluA2 cryst1 receptor, together with the nanomolar affinity modulator (R,R)-2b and either KA or FW, we were able to grow single crystals of the receptor complex that diffract x-rays to between 3.5 and 4 Å resolution. To further address how agonist binding is coupled to ion channel gating, we resolved the structures of two Lurcher-like mutants (13) within the M3 ion channel gate region (14) .
Architecture of AMPA receptor-toxin complex
The overall shape of the GluA2 receptor complex with con-ikot-ikot, (R,R)-2b, and either KA or FW resembles the letter Y, reminiscent of the preceding GluA2 antagonist complex (Fig. 1 , A to D) (6) . The toxin is entirely enshrouded within a large solvent-filled chamber between the ATD and LBD layers, thus providing molecular explanations for its slow on rate and potent activity (8) and requiring movement of the ATDs and/or ATD-LBD portals for binding or unbinding. By wedging between the ATD and LBD layers, the toxin buttresses the receptor complex, extending the height of the ATD to LBD layer by nearly 10 Å, as measured from the centers of masses (COMs) between the ATD and the D1 lobe of the LBD. The boomerang-shaped toxin spans LBD dimers, with interactions both within and between LBD dimers, burying 2128 Å 2 of surface area in the interface and aligning its molecular twofold axis with the overall twofold axis of the receptor. Despite proximity to the "overhanging" ATD layer, the toxin participates in few contacts with the ATD, thus explaining why DATD AMPA receptor complexes retain toxin sensitivity (8) .
The 1.6 Å-resolution crystal structure of the isolated toxin unambiguously shows that it is a dimeric complex, in contrast to previous suggestions that it was a dimer of dimers (Fig. 1 , E and F) (8) . The size-exclusion chromatography profile of the toxin confirms that it behaves as a dimer in solution ( fig. S1, A and B) . Each subunit of the homodimeric toxin harbors a fourhelix bundle that is extensively cross-linked by five disulfide bonds and is, in turn, linked to the second subunit by way of three intersubunit disulfide bonds ( fig. S1C ), yielding a robustly rigidified complex in which the only region of flexibility resides in the subunit-subunit interface. The boomerang-shaped homodimer has a conspicuous pattern of charged residues and nonpolar residues on its surface, with a prominent acidic patch defined by E48 (E, Glu) and the carboxyl terminus of A86 (A, Ala) (Fig. 1F) , and hydrophobic regions resulting from exposed nonpolar residues of F34 and I61 (F, Phe; I, Ile).
The con-ikot-ikot structure provides a framework to understand the structure and function of other family members.
Complex web of receptor-toxin interactions
Con-ikot-ikot toxin spans the tetrameric LBD "gating ring," participating in extensive interactions with all four subunits such that it simultaneously fortifies intradimer interfaces and spans the interdimer cleft (Fig. 2) . The electrostatic surface of the toxin "bottom" (Fig. 1F) shows extensive negative patches, which are complementary to multiple positively charged residues on the receptor surface, suggesting that ionic and polar contacts are crucial for receptortoxin interaction ( Fig. 2A) . Furthermore, the convex face of the boomerang-shaped toxin is complementary to the concave receptor binding site, demonstrating that shape is also central to nanomolar toxin binding affinity (8) .
To more precisely understand the mechanism by which the toxin blocks desensitization, we peeled away the toxin from its LBD binding site to give open-book views of the receptor-toxin interface (Fig. 2, A and B) . The receptor-toxin interactions can be classified into two types of contacts on the basis of the positions of subunits in the receptor complex (6), namely, LBD proximal A/C subunit-toxin interactions and distal B/D subunit-toxin interactions. Crucial contacts are between the extreme C-terminal carboxyl group of the toxin (A86) and the ammonium group of K752 (K, Lys) from the LBD B/D pair D1 lobe (Fig. 2E ) and between the side-chain carboxyl group of toxin residue E48 and the side-chain guanidine group of R660 (R, Arg) from the LBD A/C pair D2 lobe (Fig. 2F ). Augmenting these interactions is a polar contact between the side-chain carbonyl group of toxin Q37 (Q, Gln) and the side-chain guanidine group of R453 from LBD A/C pair D1 lobe. These residues on the GluA2 receptor are conserved in AMPA-subtype iGluRs but not in KA or NMDA receptors ( fig. S3A ), which is consistent with previous findings that con-ikot-ikot only potentiates the activity of AMPA receptors (8) . To validate the interactions we observed in the receptor-toxin crystal structure, we mutated the residues on GluA2 to the corresponding residues on KA receptors and measured the extent to which toxin potentiates the activity of the mutants in comparison with cyclothiazide (CTZ) (15) . Although all of the mutants respond to CTZ, potentiation by toxin is reduced, and, for the double mutant of R453→Q453 (R453Q)/ K752Q, toxin potentiation is ablated (Fig. 2C) . Additionally, the R660K mutant desensitizes profoundly, on the basis of the magnitude of CTZ potentiation. This might be because R660 indirectly decreases LBD dimer stability and thus promotes desensitization.
On the basis of extensive structural and functional studies of soluble LBDs (sLBD), the LBD undergoes clamshell-like domain closure upon agonist binding, and the degree of domain closure is correlated with agonist efficacy (11, 16) , although partial agonists may nevertheless occupy the fully closed state, albeit with reduced probability (17) . Because the toxin interacts with both D1 and D2 lobes of the LBD A/C pair of subunits, we compared the KA-bound structure with the FW-bound structure by superposing the toxin domains ( fig. S3B ). Although the D2 lobes of the two structures are almost superimposable, the D1 lobe shows an outward displacement in the KA-bound structure compared with the FW-bound structure, as evidenced by a 3-Å shift of the marker Ca atom of K458 of the A/C pair, which is on b4 of the D1 lobe and in close proximity to R453. This conformational difference is consistent with the degree of clamshell closure both in full-length structures (fig. S3, E and F) and in sLBDs (11, 18, 19) , which show that the KA clamshells are more open in comparison to the FW subunits. Nevertheless, a change in rotamer conformation of toxin residue Q37 allows it to maintain its interaction with receptor residue R453 in both complexes ( fig. S3C ), thus showing how the toxin can interact with the receptor in the presence of KA or FW, despite differences in the degree of LBD clamshell closure. However, if we model a hypothetical complex of the toxin with an apo receptor subunit by superposing the D2 lobe of the apo sLBD (19) [Protein Data Bank (PDB) 1FTO chain A] structure onto the KA-and toxin-bound structure, there is a further 7-Å outward shift of the K458 Ca marker atom so that Q37 of the toxin can no longer interact with R453 of the LBD ( fig. S3C) . Indeed, in a toxin binding assay we show that receptor-toxin complex formation requires the presence of agonist ( fig. S3D ). Thus, receptor-toxin binding requires ligands that induce clamshell closure. Because the toxin binds to both D1 and D2 lobes of the LBD A/C pair, the LBD is stabilized in a ligand-bound conformation. Consistent with the mechanism, toxin increases apparent agonist affinity in a 3 H FW-binding assay ( fig. S2F ), and previous studies have shown that toxin can modestly retard the rate of receptor deactivation (8) .
Conformation of the LBD layer in an activated state
The interaxis or "roll" angle (20) between the twofold axes of the LBD dimers is smaller in the toxin complex than in the ZK 200775 (ZK) antagonist-bound structure (Fig. 3, A to C) , largely because the toxin locks the LBD gating ring in a fixed conformation. Furthermore, the toxin structure with FW bound has a smaller interaxis angle than the KA complex (Fig. 3, B and C) because the D2 lobes, which are coupled to the ion channel, share a common position, but the FW complex has a greater LBD domain closure. Thus, there is a corresponding difference in the position of the D1 lobes ( fig. S3, E and F) . By binding both subunits within a LBD dimer, the toxin stabilizes the LBD dimer D1-D1 interface in a nondesensitized conformation, yielding a distance between S741 (S, Ser) Ca marker atoms on the D1-D1 interface of 19.3 to 19.7 Å (21, 22) . By using the distance between Ca atoms of S741 residues in the D1-D1 interface as a metric, we show that the D1-D1 interfaces adopt nondesensitized conformations in all of the structures (Fig. 3, D, to F) . The toxin complexes reported here also have the modulator (R,R)-2b bound because inclusion of modulator improves diffraction quality, presumably by stabilizing the receptor in a conformationally homogeneous population.
In comparison to the GluA2 ZK structure [Protein Data Bank (PDB) code 3KG2] (6), the toxin complex structures with either KA or FW bound have much larger degrees of clamshell closure and thus a larger separation of the D2 lobe within dimers. To quantify the separation of the D2 lobes, we compared the distances between S640 Ca marker atoms, which are on helix E of the D2 lobe and directly connected to the D2-M3 linker. There is an 8.4-Å increase in separation between the D2 lobes upon transition from the ZK antagonist state to the FW agonistbound structure, thus providing structural evidence for the long-standing hypothesis that LBD domain closure is mechanically coupled to ion channel gating (19, 21) (Fig. 3, G to I ), thus suggesting that there is a nonequivalent "pulling force" of the LBDs onto the LBD-TMD linker (23), consistent with the symmetry nonequivalence of the A/C and B/D subunit pairs (6).
Toxin stabilization of LBD gating ring
A view of the LBD layer from the ATD shows how the toxin stabilizes the LBD layer in an expanded conformation (Fig. 4) . By measuring the distances between Ca marker atoms of R660 on helix F and Q756 on helix J, both of which are close to the central opening of the gating ring, we compared the interdimer distances between selected structures. Beginning with the A665C cross-linked sLBD tetramer (Fig. 4, A and D) (24), which is trapped in an inactive state yet has been suggested to represent an activation intermediate, and then to the ZK state (Fig. 4 , B and D) and last to the toxin-and FW-bound state (Fig. 4, C and D) , we observed an increase of the B/D distance from 16.5 to 23.9 to 27.4 Å, respectively, whereas the A/C distance changed from 19.7 to 24.1 to 22.0 Å, respectively. The overall change in the B/D distances is larger in comparison to the change in the A/C pair, an observation that is correlated with the changes in the S640 Ca distances mentioned previously and consistent with the hypothesis that the B/D pair may play a more important role in ion channel opening. We suggest that, without toxin, the LBD dimers are more conformationally dynamic SCIENCE sciencemag.org 29 and can adopt different conformations because of the relatively small interdimer interface (25) .
Coupling of agonist binding to channel gating via M3-D2 linker
The channel pore of the toxin-GluA2 complex structure with either KA or FW adopts the same closed conformation as the ZK-bound structure (6), although there is a small conformational change at the upper region of the crucial M3 helix between residues 623 and 626 (Fig. 5, A  and D) . In the toxin-complex structures, the LBD dimer interfaces are intact and stabilized by both toxin and modulator. In addition, partial agonists are bound and induce LBD clamshell closure; thus, we propose that these structures represent toxin-bound preopen states. However, the ion channel gate is closed at the M3 bundle crossing, and we speculate that this is because either the crystallization conditions, the absence of lipid bilayer, or the details of the receptor construct favor a closed-gate conformation. It is also possible that the use of partial agonists does not sufficiently populate the open-gate conformation (11) . To address the issue of the receptor construct, we solved the structure of GluA2 cryst2 in complex with KA+toxin+(R,R)-2b, where the GluA2 cryst2 construct only harbors the C815A (C, Cys) mutation, located at the C-terminal end of the M4 helix. The structure of this GluA2 cryst2 complex is similar to the corresponding GluA2 cryst1 structure ( fig. S5 , C and D; overall root mean square deviation of 0.28 Å on main chain atoms), thus demonstrating that other factors are responsible for precluding the crystallization of an opengate conformation.
To favor the formation of an open state, we generated the Lurcher-like mutants A622T (26) and T625G (G, Gly; T, Thr) (27) in the context of the GluA2 cryst1 construct, mutations that are known to greatly facilitate ion channel gating. Structures of these mutants as complexes with KA+toxin+(R,R)-2b showed large conformational changes only within the M3-LBD linkers compared with the structure without the activation mutations (Fig. 5 and fig. S6 ). Complexes with full agonists or with more-efficacious partial agonists have so far not yielded crystals. Because the structures of the T625G and A622T variants are close to identical, we focused the discussion on the A622T structure unless indicated. In the mutant structures, the side chain of I633 from the B/D subunits binds within a hydrophobic pocket formed by V732, I504, L639, and I645 (L, Leu; V, Val) on the D2 lobe of the LBDs, adopting the same binding mode as I633 from the A/C pair or all subunits from the ZK structure (Fig. 5F) ; we term this the coupled conformation. By contrast, I633 from the B/D pair in the toxin-bound structures without the M3 mutations is pulled out of the hydrophobic D2 pocket and adopts an uncoupled conformation (Fig. 5C) .
To better define the register of the region flanking I633, we generated the S635C mutant in a GluA2 cryst1 background and labeled the resulting protein with mercury. In anomalous difference electron density maps at the LBD-TMD linker region of the S635C mutant, we see density at the A/C subunit positions but no prominent density for the B/D subunits ( fig. S5G) . Assuming that the sites have similar labeling efficiencies, we can conclude that the S635C sites in the B/D pair are mobile, consistent with a dynamic linker region. However, the electron density is sufficiently strong to unambiguously trace the main chain, which shows that the I633 side chain cannot adopt a coupled conformation in the non-M3 mutant structures. To further probe the role of I633, we generated I633A and I633E mutants in the background of the wild-type receptor, hypothesizing that these mutants would favor an uncoupled conformation and thus diminish agonistinduced gating. Indeed, the I633A mutant shows only very small currents compared with wild-type GluA2 ( fig. S4, A, D, and J) , whereas the I633E mutant shows even smaller currents ( fig. S4 , G and J). Both receptor assembly, as assessed by FSEC ( fig. S4 , B, E, and H), and receptor surface expression are similar to those of the wild-type receptor ( fig. S4, C, F, I , K, and L). These results are consistent with the conclusion that the I633 mutant has impaired gating, perhaps similar to the recently reported glycine-insertion mutants of the NMDA receptor LBD-M3 linker (23) . Indeed, the I633 position is conserved in iGluRs, with the exception that, in the NMDA receptor GluN2 subunit, there is a valine at this site ( fig. S4N ). Because the uncoupled phenotype of the I633A mutant can be robustly rescued by coexpression with transmembrane AMPA receptor regulatory protein g2 (TARPg2) (28) (fig. S4M) , an AMPA receptor auxiliary subunit that enhances receptor activation, we show that the I633A mutant is properly folded and assembled yet likely has a low open probability in the absence of TARPg2.
The activation mutant structures show that conformational changes of key gating residues near the M3 helix crossing are more prominent in the B/D subunits than in the A/C subunits (Fig. 5, A and D) . As identified in the ZK-bound structure, T617, A621, T625, and M629 (M, Met) form the physically shut gate of the channel (6). In the activation mutant structures, the outward movements of the Ca atoms in B/D subunits start at A620, increase in the direction of the extracellular ends of the M3 segments (Fig.  5A) , and involve the unwinding of the last turn of the M3 helix. By contrast with the large changes in the upper region of the M3 helix of the B/D subunits, there are only small changes in the lower region of the B/D subunits, Nterminal to T617, and only small changes in the entire M3 segment from the A/C subunits. Together, these results show that the pore is still shut and that the upper M3 helix transforms from fourfold symmetry to twofold symmetry in transitioning from the cytoplasmic to the extracellular side of the membrane (29) .
The coupled I633 position and the outward movements of the upper regions of the M3 segments in the B/D subunits are consistent with the mutant structures reflecting an activation intermediate state (Fig. 5H) between the toxin-bound structure (Fig. 5G ) and a hypothetical fully opened structure (Fig. 5I) . Lurcher-like mutants may facilitate current flow by weakening the M3 helix bundle, allowing the ion channel gate to open more easily. In our structures, however, the ion channel has not opened, and instead the mutants have simply facilitated the distortion of the extracellular end of the M3 helix.
We suggest that I633 must be in a coupled position to transmit agonist binding and clamshell closure to gate opening and, secondly, that the unwinding of the M3 helix tip can absorb the pulling force generated by LBD. When we modeled I633 in a coupled state, we found that the linker is not of sufficient length to permit the combination of an activated LBD (closed clamshell) and a closed pore ( fig. S6C) . Thus, we speculate that, in the fully opened structure, I633 is coupled, the M3 tip preserves its helical structure, and the M3 helix is flexed or kinked outward to allow for an open channel gate.
Conclusion
We show that con-ikot-ikot toxin binds between ATD and LBD layers, forms extensive contacts with all four LBD subunits, and stabilizes the LBD gating ring in an activation-competent conformation. The cross-linking of the LBDs precludes the rupture of the D1-D1 interface, locks the LBD dimers together, and allows for agonist binding to be coupled to ion channel gating. By comparing agonist-bound toxin-receptor structures to the previously determined antagonistreceptor complex (movies S1 and S2), we show how agonist binding is coupled to ion channel gating, thus validating decades of research on the isolated binding domains of iGluRs. We propose that agonist binding generates an asymmetric pulling force on the LBD-TMD linker and that a previously unidentified coupling switch defined by I633 is crucial to convey clamshell closure to channel opening. Taken together, the toxin-bound GluA2 structures provide insight into the gating mechanism of AMPA receptors and shed light on mechanisms of closely related KA and NMDA receptors. Insight into how AMPA receptor activity is modulated may also open new avenues for the development of therapeutic agents.
